Adalimumab-Bwwd

Introduction Overview

Generic Name

adalimumab-bwwd

Brand Name

Hadlima

Dosage Form

Subcutaneous solution (injection)

Drug Class

TNF alpha inhibitors

Pharmacokinetics

Absorption:
Adalimumab-bwwd is a fully human monoclonal antibody administered subcutaneously. After subcutaneous injection, it is slowly absorbed into the systemic circulation, with a bioavailability of approximately 64%. Peak plasma concentrations occur between 131 to 177 hours (5.5 to 7.4 days) post-dose. Absorption rates may be influenced by injection site, local blood flow, and lymphatic system function. Being a large protein molecule, it does not undergo absorption via traditional gastrointestinal routes.

Distribution:
The volume of distribution for adalimumab is approximately 4.7 L, indicating limited distribution primarily within the vascular and interstitial compartments. Due to its large molecular weight (~150 kDa), it does not cross cell membranes readily or penetrate the central nervous system. Adalimumab binds TNF-alpha molecules extracellularly, predominantly in inflamed tissues where TNF-alpha is overexpressed. The distribution may be influenced by factors such as disease state and presence of antibodies against the drug.

Metabolism:
As a monoclonal antibody, adalimumab is metabolized through proteolytic catabolism to peptides and amino acids via the reticuloendothelial system commonly involved in protein degradation. Unlike small molecule drugs, adalimumab is not metabolized by cytochrome P450 enzymes and thus is unlikely to have interactions related to hepatic enzyme metabolism. Metabolic clearance may be affected by the presence of anti-drug antibodies, disease factors, and body weight.

Elimination:
Elimination of adalimumab occurs via non-specific catabolism by the reticuloendothelial system; it is not eliminated renally or hepatically in any significant manner. The median terminal half-life is approximately 10 to 20 days, allowing for dosing intervals typically every two weeks or longer depending on indication and patient response. Factors such as anti-adalimumab antibody formation may enhance clearance, reducing systemic exposure and possibly efficacy. Clearance may also be increased in patients with higher body weight. The drug's elimination kinetics warrant considerations in dose adjustments and monitoring therapeutic levels during treatment.

Dosage Forms

Available Dosage Forms:
- Subcutaneous injection solution delivered via prefilled syringe or autoinjector
- Concentrations/formulations specific to Hadlima include:
- Autoinjector: 40 mg/0.4 mL and 40 mg/0.8 mL
- Pre-filled syringe: 40 mg/0.4 mL, 40 mg/0.8 mL
- Single-dose vial: 40 mg/0.8 mL

Dosages for Adults and Adolescents:
- Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis:
- Adults: 40 mg subcutaneously every other week; dose adjustments permitted by physician
- Crohn's disease:
- Adults and children ≥6 years and ≥40 kg: Initial 160 mg on day 1 (administered as four 40 mg injections in one day or two injections per day for two days), 80 mg at week 2, then 40 mg every other week from week 4 onward
- Children 6 years and weighing 17 to <40 kg: Initial 80 mg on day 1, then 40 mg at week 2, maintenance 20 mg every other week from week 4
- Plaque psoriasis and uveitis:
- Adults: Initial 80 mg, then 40 mg one week later, then every other week
- Juvenile idiopathic arthritis:
- Children 2 years and older:
- ≥30 kg: 40 mg every other week
- 15 to <30 kg: 20 mg every other week
- 10 to <15 kg: 10 mg every other week
- Hidradenitis suppurativa:
- Adults: Initial 160 mg on day 1, then 80 mg at week 2, maintenance 40 mg weekly or 80 mg every other week from week 4

Specific Patient Populations:
- Pediatric use varies by condition, with established dosing supported in juvenile idiopathic arthritis (≥2 years) and Crohn’s disease (≥6 years), with doses adjusted by weight
- Use in children younger than 2 years (for JIA) and under 6 years (for Crohn’s) lacks established safety and efficacy
- In elderly patients, cautious use recommended due to increased risk of serious infections and malignancies
- Patients with severe renal or hepatic impairment do not require specific dose adjustments, but clinical monitoring recommended
- Dose modifications may be necessary in cases of adverse reactions or immunogenicity
- Patient education on self-injection techniques, site rotation, and storage conditions is essential for safe administration and optimal efficacy.

Mechanism Of Action

Hadlima (adalimumab-bwwd) is a recombinant human IgG1 monoclonal antibody that specifically binds to tumor necrosis factor-alpha (TNF-alpha), a pro-inflammatory cytokine central to the pathogenesis of various autoimmune and inflammatory diseases. Through high-affinity binding to soluble and transmembrane forms of TNF-alpha, Hadlima neutralizes its biological activity by preventing interaction with TNF receptors 1 and 2 (TNFR1 and TNFR2) on cell surfaces.

Blocking TNF-alpha leads to the downregulation of inflammatory cascades, reduction of leukocyte migration into inflamed tissues, and decreased expression of adhesion molecules, cytokines, and chemokines. This mechanism interrupts the chronic inflammatory cycle observed in diseases such as rheumatoid arthritis, Crohn's disease, psoriatic arthritis, and plaque psoriasis.

At the cellular level, Hadlima binding to transmembrane TNF-alpha can induce apoptosis of TNF-expressing cells and may modulate immune cell activity. This effect contributes both to dampening inflammatory cell populations and to modulating immune responses in affected tissues.

Comparatively, Hadlima shares its mechanism with other TNF-alpha inhibitors like infliximab and etanercept, though differences in molecular structure and binding epitopes may influence pharmacodynamics and immunogenicity. Clinical studies have demonstrated Hadlima’s equivalence in efficacy and safety to the reference product Humira (adalimumab), supporting its use as a biosimilar TNF-blocking agent.

The clinical implications of this targeted inhibitory mechanism allow for control of disease activity, prevention of joint destruction in arthritis, healing of inflammatory bowel lesions, and improvement of psoriatic skin lesions without the broad immunosuppression associated with traditional systemic therapies. However, TNF inhibition carries risks including increased susceptibility to infections and malignancies, necessitating careful patient screening and monitoring.

Pharmacological Actions

Selective inhibition of tumor necrosis factor-alpha (TNF-alpha) activity
Neutralization of both soluble and transmembrane TNF-alpha molecules
Reduction of pro-inflammatory cytokine signaling pathways
Suppression of leukocyte recruitment and infiltration into inflamed tissues
Induction of apoptosis in TNF-expressing cells
Modulation of immune cell function leading to decreased inflammation
Prevention of joint damage in autoimmune arthritis via downregulation of inflammatory mediators
Reduction of mucosal inflammation in Crohn's disease and ulcerative colitis
Improvement of epidermal turnover and plaque formation in psoriasis
Attenuation of inflammatory nodules in hidradenitis suppurativa
Control of ocular inflammation in non-infectious uveitis
Demonstration of biosimilar activity equivalent to reference adalimumab product
Immunomodulatory effects without broad immunosuppression
Long half-life allows for biweekly or less frequent dosing schedules

Therapeutic Or Clinical Uses

Treatment of moderate to severely active rheumatoid arthritis in adults and children
Management of active ankylosing spondylitis
Treatment of juvenile idiopathic arthritis in children 2 years and older
Management of psoriatic arthritis with or without psoriasis
Induction and maintenance treatment of moderate to severe Crohn's disease in adults and pediatric patients
Treatment of moderate to severe active ulcerative colitis
Management of moderate to severe chronic plaque psoriasis in patients requiring systemic therapy
Treatment of moderate to severe hidradenitis suppurativa
Management of non-infectious intermediate, posterior, and panuveitis
Used as monotherapy or in combination with other disease-modifying antirheumatic drugs (e.g., methotrexate)
Reduction of symptoms, inflammation, and progression of disease activity in autoimmune disorders
Improvement of quality of life in patients with chronic inflammatory conditions
Alternative therapeutic option for patients intolerant or refractory to conventional therapies
Utilized off-label in selected inflammatory conditions under medical supervision
Part of biosimilar therapeutic class providing cost-effective TNF blocker therapy

Side Or Adverse Effects

Injection site reactions including pain, redness, swelling, and itching
Increased risk of serious infections such as tuberculosis, bacterial sepsis, and invasive fungal infections
Upper respiratory tract infections including cough, sore throat, and sinusitis
Headache and dizziness
Nausea, abdominal pain, and gastrointestinal disturbances
Allergic reactions ranging from mild hypersensitivity to anaphylaxis and angioneurotic edema
Hematologic abnormalities such as leukopenia, thrombocytopenia, and anemia
Development of malignancies including lymphoma and hepatosplenic T-cell lymphoma especially in pediatric and adolescent patients
Potential lupus-like syndrome with symptoms of rash, joint pain, and chest discomfort
Neurologic effects including demyelinating disease, optic neuritis, and seizures
Severe dermatological reactions such as blistering, peeling, or skin rash
Elevated liver enzymes and rare cases of hepatotoxicity
Congestive heart failure exacerbation or new onset
Fatigue, malaise, and unintentional weight changes
Visual disturbances and eye pain

Precautions

Screen for latent tuberculosis prior to initiation and monitor during therapy
Avoid administration in patients with active infections or a history of recurrent infections
Monitor complete blood counts regularly due to risk of cytopenias
Use caution in patients with congestive heart failure; monitor for new or worsening symptoms
Avoid live vaccines during and following treatment until immune function is restored
Assess history of malignancy; use caution particularly in pediatric and adolescent patients
Screen for demyelinating neurological disorders before starting therapy
Pregnancy and breastfeeding considerations require risk-benefit assessment due to limited safety data
Advise patients on injection site care and proper administration technique
Monitor for signs of allergic or anaphylactic reactions following injection
Avoid concomitant use with other biologic immunosuppressants such as abatacept or anakinra unless under close medical supervision
Patients should avoid exposure to individuals with contagious infections
Educate patients to report any unusual bleeding, bruising, or persistent fever promptly
Consider dose adjustments or discontinuation upon serious adverse event occurrence
Monitor for the development of lupus-like syndrome and discontinue if symptoms arise

Warnings

Increased risk of serious infections including tuberculosis, bacterial, and invasive fungal infections which can lead to hospitalization or death
Potential for malignancies including lymphoma, especially hepatosplenic T-cell lymphoma in adolescents and young adults
Risk of severe allergic reactions and anaphylaxis requiring immediate medical attention
Use may exacerbate or cause new onset congestive heart failure
Possible induction or exacerbation of demyelinating disorders such as multiple sclerosis
Development of lupus-like syndrome which may resolve upon discontinuation
Immunosuppression leading to increased risk of opportunistic infections
Potential for hematologic toxicities such as pancytopenia and aplastic anemia
Not recommended in patients with active infections until infection is controlled
Avoid live vaccines during treatment due to risk of disseminated infection
Monitor pediatric patients carefully given the risk of malignancies and infections
Risk of injection site reactions including local infection
Use caution in patients with chronic obstructive pulmonary disease because it may increase infection risk
Abrupt discontinuation can lead to disease flare; dose adjustments should be physician-guided
Patients should be counseled about symptoms indicative of infection or malignancy

Contraindication

Known hypersensitivity to adalimumab or any component of the formulation
Active, untreated tuberculosis or other active severe infections
Severe infections such as sepsis or opportunistic infections
Use of live vaccines during therapy
History of hypersensitivity reactions to other TNF inhibitors if deemed at high risk
Patients with known demyelinating disease or multiple sclerosis without careful assessment
Patients with moderate to severe heart failure (NYHA class III/IV)
Concurrent use with other biologic immunosuppressives (e.g., abatacept, anakinra) due to increased infection risk
Known lymphoma or malignancy where immunosuppression is contraindicated
Patients with active hepatitis B virus infection not under treatment
Hypersensitivity to latex if exposed to latex-containing delivery devices
Patients receiving concurrent live vaccinations

Drug Interactions

Increased risk of infection when used concomitantly with other immunosuppressive agents such as methotrexate and cyclosporine
Potential additive immunosuppressive effects when combined with other biologic agents like abatacept or anakinra, generally contraindicated
Avoid concurrent administration with live vaccines due to risk of disseminated infection
Possible pharmacodynamic interactions with warfarin requiring monitoring of anticoagulation parameters
No significant cytochrome P450 enzyme-mediated interactions expected
Potential reduced efficacy or immunogenicity development with lowered dosing intervals or improper administration
Interactions with certain live virus vaccines such as measles, mumps, rubella, varicella leading to increased risk of vaccine-related infections
Live vaccines including Bacillus Calmette-Guerin (BCG), yellow fever, influenza (live attenuated) are contraindicated during therapy
Theophylline levels may be affected; monitoring advised when co-administered
Avoid administration with certain investigational agents unless benefits outweigh risks and under clinical supervision
Concurrent use of TNF blockers may increase hematologic toxicity risk
Potential additive hematological or immunologic adverse effects with concurrent chemotherapy or radiation therapy
Concomitant use with corticosteroids may increase infection risk
Alcohol and tobacco use may exacerbate immunosuppression risks and should be discussed with patients
No known significant interactions with food, but patients should maintain consistent habits

Preparations Of The Drug

Hadlima is supplied as a subcutaneous injection solution in the following preparations:
- Autoinjector: 40 mg/0.4 mL and 40 mg/0.8 mL prefilled autoinjector devices
- Prefilled syringe: 40 mg/0.4 mL and 40 mg/0.8 mL disposable syringe setups for manual injection
- Single-dose vial: 40 mg/0.8 mL single-use vial for injection
All preparations consist of sterile, preservative-free, clear to slightly opalescent, colorless to pale brown solutions
Packaging designed for single-patient use with no preservatives to minimize risk of contamination
Storage requires refrigeration at 2°C to 8°C (36°F to 46°F) with protection from light; do not freeze
May be stored at room temperature (below 25°C) for up to 14 days if necessary (e.g., during travel), but should not be returned to refrigeration after warming
Disposal of needles and syringes must follow local regulations for biomedical waste; use puncture-resistant containers
Injection devices are user-friendly to facilitate self-administration with instructions and training provided by healthcare professionals
No oral, topical, or intravenous preparations available under the Hadlima brand name
No known preservatives or additives that interfere with immunogenicity
Parenteral delivery ensures rapid systemic bioavailability consistent with monoclonal antibody pharmacokinetics
Compatible with certain diluents used in biosimilar manufacturing but must not be mixed with other drugs in the same syringe